Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 700-380-4 | CAS number: -
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Key value for chemical safety assessment
Additional information
Inhalation absorption
The potential for dust inhalation is considered to be of no relevance, since the substance at room temperature (20-25°C) is a liquid to waxy solid and not a powder with an inhalable size.Taking into account the vapour pressure of 3*10-5Pa at 25°C of SymMollient®S and the low water solubility(A: 3.5 µg/L/ B: 1.7 µg/L) inhalation of vapours can also be completely ruled out.
Oral absorption
SymMollient® S is of low water soluble (A: 3.5 µg/L/ B: 1.7 µg/L) and highly lipophilic (log Pow (calculated) = 11.2 / 12.2), therefore absorption may be limited by the lowability to dissolve in GI fluids and hence to be available in soluble form at the mucosal surface. However, the absorption will be enhanced if they undergo micellular solubilisation by bile salts.
Dermal absorption
SymMollient® S is intended to be used at a low application rate as a topical skin care product to regulate the moisture content of the skin by forming alight hydrophobic film on the skin that protects from drying out.
Based on the low water solubility (A: 3.5 µg/L/ B: 1.7 µg/L) and the high lipophilicity (logPow (calculated) = 11.2 / 12.2), quantitatively relevant dermal absorption cannot completely ruled out on the basis of theoretical considerations only.
Distribution
The substance is expected to reach the systemic circulation only to a very limited extend and in addition it is expected to be readily metabolised after passing the liver. Therefore, distribution SymMollient® S throughout the body is not very likely.
Metabolism and elimination
The carboxylesterase hydrolyses the carboxylic esters into a carboxylate and alcohol.
The alcohol will be oxidised in the liver to an aldehyde, catalysed by the alcohol/dehydrogenase containing the coenzyme NAD+. The aldehyde is further oxidised to the respective carboxylate. Both carboxylates will be broken down into acetyl-CoA-units, which will be metabolised in the citrate cycle just like the conventional metabolism of natural fatty acids, ultimately yielding carbon dioxide as respiration product.
In consequence, if small amounts of SymMollient® S reach the systemic circulation, the substance may be expected to be readily biotransformed to harmless, endogenous cellular constituents of the energy-producing metabolic pathway.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
